Ownership Is Increased to 95%

SAN ANTONIO, TX, June 18, 2008 – OncoVista Innovative Therapies Inc. (OTC BB: OVIT.OB), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics, today announced that it has successfully completed the acquisition of additional shares of AdnaGen AG (Hanover, Germany), increasing its ownership from 85% to over 95% of the issued and outstanding shares of the company.

SAN ANTONIO, TX, May 8, 2008 - OncoVista Innovative Therapies, Inc. (OTCBB:OVIT), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies, announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. 

SAN ANTONIO, TX, May 6, 2008 – OncoVista Innovative Therapies Inc. (OTC BB: OVIT.OB), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies, announced the submission of a request to the U.S. Food and Drug Administration for a pre-IDE determination meeting for the AndaGen AdnaTest Breast Cancer device for the detection of circulating breast tumor cells.